DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel JUN2021 Cycle 38 NExT SEP Committee Meeting

Date: August 4, 2021

Time: 9:00 AM to 3:00 PM

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio

Place: National Institutes of Health
9000 Rockville Pike
Building 31, Room 3A44
Bethesda, Maryland 20892
(WebEx Meeting)

Contact Persons: Barbara Mroczkowski, Ph.D.
Executive Secretary
Discovery Experimental Therapeutics Program
National Cancer Institute, NIH
31 Center Drive, Room 3A44
Dated: July 12, 2021.

Melanie J. Pantoja,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2021-15073 Filed: 7/14/2021 8:45 am; Publication Date: 7/15/2021]